Want to see INBS full AI Analyst Report?
Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▼(-15.25% Downside)
Action:Reiterated
Date:09/09/26
The score is held down primarily by weak financial quality—large ongoing losses, declining gross margin, and significant persistent free-cash-flow burn—despite improving revenue. Technicals also remain soft with the stock trading below major moving averages. Offsetting these negatives, recent corporate events are meaningfully positive, highlighted by the FDA 510(k) submission backed by strong reported study results and additional funding raised via private placement.
Positive Factors
Revenue Growth
The increase in trailing revenue indicates improving commercial traction for the screening platform and consumables. If sustained, broader customer adoption can build a recurring testing base, support operating leverage, and strengthen INBS's position in workplace and safety-sensitive testing markets.
Negative Factors
Persistent Cash Burn
Persistent cash outflows mean the business is not yet self-funding and must continue using cash or raising capital to sustain operations. If revenue growth does not quickly improve operating leverage, financing needs could constrain strategic flexibility and increase execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The increase in trailing revenue indicates improving commercial traction for the screening platform and consumables. If sustained, broader customer adoption can build a recurring testing base, support operating leverage, and strengthen INBS's position in workplace and safety-sensitive testing markets.
Read all positive factors
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.47M
Dividend YieldN/A
Average Volume (3M)257.05K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth38.09%
EPS Growth54.22%
CountryUS
Employees59
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-9.46
Shares Outstanding3,316,803
10 Day Avg. Volume40,829
30 Day Avg. Volume257,045
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.61
Price to Sales (P/S)0.80
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.18
Revenue Forecast (FY)$6.13M
Intelligent Bio Solutions Business Overview & Revenue Model
Company Description
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the S...
How the Company Makes Money
INBS primarily makes money by selling and distributing its rapid drug screening system and the recurring consumables used with it. Key revenue streams include: (1) sales of the screening platform/instrument to customers and channel partners; (2) o...
Intelligent Bio Solutions Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.22M | 3.05M | 3.11M | 1.26M | 0.00 |
| Gross Profit | 2.05M | 1.25M | 1.43M | 326.67K | 0.00 |
| EBITDA | -11.29M | -9.45M | -9.05M | -9.47M | -8.33M |
| Net Income | -12.43M | -10.57M | -10.16M | -10.63M | -8.31M |
Balance Sheet | |||||
| Total Assets | 11.94M | 8.25M | 13.78M | 10.35M | 12.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.99M | 1.02M | 6.30M | 1.54M | 8.28M |
| Total Debt | 1.82M | 281.81K | 1.15M | 1.92M | 0.00 |
| Total Liabilities | 6.65M | 5.44M | 5.60M | 6.67M | 5.81M |
| Stockholders Equity | 5.51M | 3.00M | 8.33M | 3.80M | 6.62M |
Cash Flow | |||||
| Free Cash Flow | -12.05M | -9.91M | -9.79M | -7.88M | -3.74M |
| Operating Cash Flow | -11.93M | -9.68M | -9.57M | -7.38M | -3.36M |
| Investing Cash Flow | -85.57K | -231.84K | -221.43K | -694.14K | -880.22K |
| Financing Cash Flow | 14.98M | 4.60M | 14.56M | 1.44M | 0.00 |
Intelligent Bio Solutions Technical Analysis
Negative
2.36
Price Trends
2.18
Negative
2.37
Negative
4.19
Negative
Market Momentum
-0.09
Positive
38.69
Neutral
7.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 2.24, above the 50-day MA of 2.18, and below the 200-day MA of 4.19, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.69 is Neutral, neither overbought nor oversold. The STOCH value of 7.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBS.
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions disclosed 58 risk factors in its most recent earnings report. Intelligent Bio Solutions reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intelligent Bio Solutions Peers Comparison
UnderperformOutperform
Sector (51)
INBS
Intelligent Bio Solutions
1.95
-11.50
-85.50%
ISPC
iSpecimen
1.33
-64.27
-97.97%
BGLC
BioNexus Gene Lab Corp
1.57
-3.92
-71.40%
BIAF
bioAffinity Technologies, Inc.
9.43
-68.12
-87.84%
Intelligent Bio Solutions Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Intelligent Bio Solutions Updates Share Capital Structure
Neutral
Sep 11, 2026
Intelligent Bio Solutions reported changes in its share capital structure following recent corporate actions. The update reflects both the exercise of prefunded warrants and the issuance of restricted shares under an advisory agreement. As a resul...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances FDA Drug Screening Filing
Positive
Sep 9, 2026
On September 9, 2026, Intelligent Bio Solutions announced it had submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The move cap...
Business Operations and StrategyPrivate Placements and Financing
Intelligent Bio Solutions Completes $5 Million Private Placement
Positive
Sep 2, 2026
On August 31, 2026, Intelligent Bio Solutions entered a securities purchase agreement with a single existing institutional investor for a private placement of common stock or pre-funded warrants, plus Series N-1 and Series N-2 warrants, priced at-...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances Fingerprint Drug Test Toward FDA
Positive
Sep 1, 2026
On September 1, 2026, Intelligent Bio Solutions Inc. reported results from a multi-site Method Comparison Study of its Intelligent Fingerprinting Drug Screening System for detecting the opiate codeine in pre-employment and workplace settings acros...
Business Operations and StrategyRegulatory Filings and Compliance
Intelligent Bio Solutions Issues Routine Investor Presentation Update
Neutral
Aug 28, 2026
On August 28, 2026, Intelligent Bio Solutions Inc. made an investor presentation available detailing its business and operations, and notified the market of this disclosure under Regulation FD. The presentation was furnished, rather than filed, un...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances FDA Fingerprinting Drug Study
Positive
Aug 11, 2026
On August 11, 2026, Intelligent Bio Solutions announced it had completed a multi-site Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, the final clinical study supporting its FDA 510(k) program for codeine detectio...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances Fingerprint Drug Screening Program
Positive
Aug 5, 2026
On August 5, 2026, Intelligent Bio Solutions announced it had completed a Usability Study for its Intelligent Fingerprinting Drug Screening System, a key component of its FDA 510(k) submission for U.S. clearance to detect the opiate codeine.Conduc...
Business Operations and StrategyPrivate Placements and Financing
Intelligent Bio Solutions Expands Share Count Through Equity Transactions
Neutral
Aug 3, 2026
Intelligent Bio Solutions Inc. reported that, following a series of equity-related transactions, its total outstanding common shares reached 3,018,188 as of the close of business on July 31, 2026. The change reflects sales under an at-the-market o...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances FDA Path with Interference Study
Positive
Aug 3, 2026
On August 3, 2026, Intelligent Bio Solutions announced it had completed an Interference Study for its Intelligent Fingerprinting Drug Screening System, a key component of its FDA 510(k) submission for codeine detection in the U.S. market. Conducte...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances FDA 510(k) Cybersecurity Readiness
Positive
Jul 23, 2026
On July 23, 2026, Intelligent Bio Solutions announced it had resolved all cybersecurity and software-related review items tied to independent penetration testing for its planned FDA 510(k) submission, completing remediation of all medium-risk vuln...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances Fingerprint Drug Screening Precision
Positive
Jul 21, 2026
On July 21, 2026, Intelligent Bio Solutions announced it had completed precision testing for its Intelligent Fingerprinting Drug Screening System aimed at detecting the opiate codeine, a key component of its FDA 510(k) submission for U.S. market c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.